Generex Biotechnology Corporatio (GNBT) 0.0078 $GNBT
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Market 2016
M2 - Thu Feb 04, 10:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/8tsk82/diabetes) has announced the addition of the "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report to their offering. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles (Sample List) - A. Menarini - Abbott Laboratories - Abbvie - Amgen - Becton, Dickinson and Company - Biocon - Biodel - BodyMedia - Boehringer Ingelheim - Bristol Myers Squibb - Cellnovo - CeQur - Flamel Technologies - Generex Biotechnology Corporation - GlaxoSmithKline PLC - Halozyme Therapeutics - Insulet - Insuline Medical Ltd. - Intarcia Therapeutics, Inc. - Janssen Research & Development - Johnson & Johnson - Novo Nordisk - Oramed Pharmaceuticals - Orexigen Therapeutics, Inc. - Owen Mumford - PhaseBio Pharmaceuticals - Pfizer - Prometheon Pharma - Roche Diagnostics - Sanofi - Valeritas - ViaCyte, Inc. (formerly Novocell) - Vivus, Inc. - vTv Therapeutics (formerly TransTech Pharma) - Ypsomed Holding For more information visit http://www.researchandmarkets.com/research/8tsk82/diabetes
OREX: 3.43 (-0.08), JNJ: 124.89 (-0.14), ABT: 43.41 (+0.24), VTVT: 5.48 (-0.10), NVO: 55.30 (-0.33), ORMP: 8.02 (-0.04), AMGN: 166.56 (+0.89), GSK: 44.04 (+0.16)
CannScience Innovations Moves to Next Stage of Product Development
CNW Group - Thu Jan 21, 6:00AM CST
Canopy Growth Corporation ("Canopy Growth" or "the Company"
(TSXV: CGC) is pleased to announce that CannScience Innovations Inc. (CSI), operating through a strategic collaboration with the University Health Network, has obtained regulatory approval to conduct research on cannabis. Canopy Growth holds a 33% ownership stake in CSI through its October 2015 acquisition of MedCannAccess.
CGC.VN: 3.240 (+0.410)
Deep Vein Thrombosis (DVT) - Global Therapeutics Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/srdbn8/deep_vein) has announced the addition of the "Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis DVT, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis DVT and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Deep Vein Thrombosis DVT Overview - Therapeutics Development - Pipeline Products for Deep Vein Thrombosis DVT - Overview - Pipeline Products for Deep Vein Thrombosis DVT - Comparative Analysis - Deep Vein Thrombosis DVT - Therapeutics under Development by Companies - Deep Vein Thrombosis DVT - Therapeutics under Investigation by Universities/Institutes - Deep Vein Thrombosis DVT - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Deep Vein Thrombosis DVT - Products under Development by Companies - Deep Vein Thrombosis DVT - Products under Investigation by Universities/Institutes - Deep Vein Thrombosis DVT - Companies Involved in Therapeutics Development - 3SBio Inc. - Archemix Corp. - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Laboratorios Farmaceuticos Rovi, S.A. - Merrion Pharmaceuticals Plc For more information visit http://www.researchandmarkets.com/research/srdbn8/deep_vein
BMY: 75.56 (-0.12)
Venous (Vein) Thrombosis Pipeline Review, H2 2015 - Analysis, Technologies & Forecasts
M2 - Thu Jan 07, 11:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/j9d7n9/venous_vein) has announced the addition of the "Venous (Vein) Thrombosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Venous (Vein) Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous (Vein) Thrombosis and special features on late-stage and discontinued projects. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Venous (Vein) Thrombosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Venous (Vein) Thrombosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Venous (Vein) Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Venous (Vein) Thrombosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - 3SBio Inc. - Archemix Corp. - Astellas Pharma Inc. - Bayer AG - Bristol-Myers Squibb Company - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Johnson & Johnson - Laboratorios Farmaceuticos Rovi, S.A. - Merrion Pharmaceuticals Plc - Nihon Pharmaceutical Industry Co., Ltd. For more information visit http://www.researchandmarkets.com/research/j9...enous_vein
JNJ: 124.89 (-0.14), BMY: 75.56 (-0.12)
Global Human Insulin Market 2015-2019 - Increasing R&D for Novel Mechanisms with Eli Lilly, Novo Nordisk & Sanofi Dominating
M2 - Fri Nov 06, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/l7t3hm/global_human) has announced the addition of the "Global Human Insulin Market 2015-2019" report to their offering. The global human insulin market to grow at a CAGR of 10.29% over the period 2014-2019 The report includes the present scenario and the growth prospects of the global human insulin market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of diabetes. The report includes a discussion of the key vendors operating in this market. The key players in the market are extending their support to academic institutions for R&D of innovative products for diabetes care. For instance, Sanofi Diabetes collaborated with academic institutions such as Helmholtz Zentrum and Charite to support R&D in the diabetes care segment. The recent collaboration of Sanofi and Gubra to discover new targets for diabetes is based on the consortium between the University of Copenhagen, Gubra and Gentofte Hospital, which is partly funded by the Danish National Advanced Technology foundation. Such collaborations enable the amalgamation of research expertise of academic institutions with the marketing intelligence of pharma companies, which is expected to support the growth of the market. According to the report, diabetes is managed by the administration of insulin on a lifelong basis. However, insulin-based therapies are incapable of controlling blood glucose levels completely and are often associated with undesirable effects such as nocturnal hypoglycemia. During the fasting stage, glucose utilization increases and free fatty acid utilization decreases in the muscle cells, leading to hypoglycemia. In addition, fat breakdown decreases and fat storage increases in the liver cells, leading to weight gain. Severe hypoglycemic events and weight gain often result in poor patient compliance. Administered insulin therapies have lesser activity in liver and more activity in the periphery as compared to that of endogenous insulin. Therefore, there is a need to develop insulin therapies with better efficacy and safety profile, which is in turn driving market growth. Further, the report states that the global human insulin market is witnessing patent expiries for major brands. Key vendors - Eli Lilly - Novo Nordisk - Sanofi Other prominent vendors - Biocon - Biodel - Biogenomics - Boehringer Ingelheim - Bristol-Myers Squibb - Diamyd Medical - Diasome Pharmaceuticals - DiaVacs - Pfizer - Generex Biotechnology - Lexicon Pharmaceuticals - Macrogenics - Merck - Oramed Pharmaceuticals - Osiris Therapeutics - Thermalin Diabetes - Tolerion - Wockhardt - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/l7...obal_human
NVO: 55.30 (-0.33), LXRX: 15.84 (+0.09), ORMP: 8.02 (-0.04), MRK: 58.56 (-0.26), OSIR: 5.01 (-0.12), LLY: 81.98 (+0.39), BMY: 75.56 (-0.12), XOMA: 0.55 (unch)
Hema Diagnostic Systems, L.L.C. Announces the Final Validation Process for a New Rapid Anthrax Ab Test
ACCESSWIRE - Thu Oct 15, 1:54PM CDT
Hema Diagnostic Systems (HDS) Announces the Final Validation Process of a New Anthrax Toxin Rapid Test for the Detection and Differentiation Between the Anthrax Protective Antigen (PA) and the Lethal Factor (LF) Using Whole Blood or Serum
Generex Announces Memorandum of Understanding in respect of a Phase II Clinical Trial for the Antigen Express Prostate Cancer Vaccine
CNW Group - Thu Oct 15, 8:30AM CDT
Antigen Express to work with CompanDX Ltd. in the UK
Generex proposes acquisition of equity interest in MediTemp
M2 - Wed Oct 14, 7:53AM CDT
Drug delivery company Generex Biotechnology (Other OTC:GNBT) disclosed on Tuesday that it has signed a non-binding Letter of Intent (LOI) with MediTemp.
Generex Announces Agreement to Acquire Equity Interest in MediTemp Ltd.
PR Newswire - Tue Oct 13, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that it has entered into a non-binding Letter of Intent (LOI) with MediTemp Ltd. (MediTemp) (www.meditemp-varicure.com), a private Israeli company that has developed a proprietary cooling technology designed to improve sperm quality in men rendered infertile due to varicoceles.
Generex Announces Agreement to Acquire Equity Interest in Alfa Rhythm Ltd.
CNW Group - Tue Oct 06, 8:30AM CDT
A unique opportunity for GNBT to expand the scope of its business
Hema Diagnostic Systems in Discussions for Equity Investment by Generex Biotechnology Corp.
ACCESSWIRE - Thu Oct 01, 11:44AM CDT
HEMA DIAGNOSTIC SYSTEMS Announces the Execution of A Non-Binding Letter Of Intent with Generex Biotechnology Corporation. HDS And Generex Will Work Together To Bring Technologies Developed By Both Companies Together By Incorporating The New And Novel Rapid Diagnostic Test Systems For Worldwide Market Expansion
Generex Announces Issuance of Buccal Cannabis White Paper
CNW Group - Thu Oct 01, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced the issuance of a white paper on the use of cannabis for medicinal purposes and the joint venture between Generex and CannScience Innovations Inc. (www.cannsci.com) for the design and development of products for the delivery of cannabinoids and cannabinoid-derived formulations into the human body via the buccal mucosa (the inner lining of the mouth).
Generex to purchase 51% equity interest in Hema Diagnostic Systems
M2 - Thu Oct 01, 4:01AM CDT
Drug delivery company Generex Biotechnology (Other OTC:GNBT) disclosed on Wednesday that it has signed a non-binding Letter of Intent (LOI) with Hema Diagnostic Systems (HDS), a Florida company that designs and manufactures proprietary infectious disease detection technologies.
Generex Announces Agreement to Acquire Equity Interest in Hema Diagnostic Systems
CNW Group - Wed Sep 30, 8:30AM CDT
Generex seeks to augment the Antigen Express work In infectious diseases with the HDS detection technologies
European Insulin Market 2015-2019 - Increase in Prevalence of Diabetes with Elli Lilly, Novo Nordisk & Sanofi Dominating the Market
M2 - Mon Sep 21, 10:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tnzhlt/insulin_market_in) has announced the addition of the "Insulin Market in Europe 2015-2019" report to their offering. The insulin market in Europe to grow at a CAGR of 6.50% over the period 2014-2019. The report, Insulin Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the insulin market in Europe and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Growing public awareness of diabetes and the available treatments will likely increase the number of people opting for these treatments. Healthcare companies are organizing awareness camps and discussions to educate people about the condition. These are conducted either alone or in combination with other national institutes. According to the report, changing lifestyle, consumption of high-fat-containing foods, and reduced physical activity increase the prevalence of obesity among the population. Obesity affects the body's normal metabolism, triggering the adipose tissues to release increased amounts of fatty acids, hormones, pro-inflammatory cytokines, and other factors, which are involved in insulin resistance. Further, the report states that the development and regulatory approval of biologic insulin and insulin analog products take longer than small molecules. Minor alterations in the physical structure and chemical pattern can significantly alter the safety and efficacy of these moieties. Unnoticeable variations in the design and execution of a manufacturing process can alter the pharmacokinetic and pharmacodynamics profiles of a drug. Key vendors - Elli Lilly - Novo Nordisk - Sanofi Other prominent vendors - Biodel - Boehringer Ingelheim - Bristol-Myers Squibb - Diamyd Medical - DiaVacs - Generex Biotechnology - Lexicon Pharmaceuticals - Macrogenics - Merck - Osiris Therapeutics - Pfizer - Tolerion - XOMA Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Insulin: An Overview - Market Landscape - Market Segmentation by Type - Buying Criteria - Market Growth Drivers - Drivers and Their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and Their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/tn..._market_in
NVO: 55.30 (-0.33), LXRX: 15.84 (+0.09), MRK: 58.56 (-0.26), OSIR: 5.01 (-0.12), BMY: 75.56 (-0.12)
Thrombosis - Pipeline Review, H1 2015
M2 - Thu Sep 10, 4:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m4rbgj/thrombosis) has announced the addition of the "Thrombosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects. the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Archemix - Arena Pharmaceuticals - Armetheon. - Arrowhead Research - Astellas Pharma - AstraZeneca - Bayer - Bristol-Myers Squibb Company - Cardax Pharmaceuticals - Cereno Scientific - China Biologic Products - CSL - Daewoong Pharmaceutical - Daiichi Sankyo - Eisai - F. Hoffmann-La Roche - Gamma Therapeutics - Generex Biotechnology - GlycoMimetics - Green Cross - IMMD - Isis Pharmaceuticals - Johnson & Johnson - Laboratorios Farmaceuticos Rovi - LG Life Sciences - Lipicard Technologies - Merrion Pharmaceuticals - Nostrum Pharmaceuticals - Pfizer - PLx Pharma - Portola Pharmaceuticals - Prothix BV - Sagene Pharmaceuticals - Sanofi - SciFluor Life Sciences - Tobira Therapeutics. - Zedira For more information visit http://www.researchandmarkets.com/research/m4rbgj/thrombosis
CBPO: 113.14 (+2.50), JNJ: 124.89 (-0.14), PTLA: 24.74 (+0.54), ISIS: 57.56 (-0.28), BMY: 75.56 (-0.12), TBRA: 4.50 (-6.75), ARNA: 1.66 (-0.02)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Market 2016
M2 - Thu Feb 04, 10:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/8tsk82/diabetes) has announced the addition of the "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report to their offering. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles (Sample List) - A. Menarini - Abbott Laboratories - Abbvie - Amgen - Becton, Dickinson and Company - Biocon - Biodel - BodyMedia - Boehringer Ingelheim - Bristol Myers Squibb - Cellnovo - CeQur - Flamel Technologies - Generex Biotechnology Corporation - GlaxoSmithKline PLC - Halozyme Therapeutics - Insulet - Insuline Medical Ltd. - Intarcia Therapeutics, Inc. - Janssen Research & Development - Johnson & Johnson - Novo Nordisk - Oramed Pharmaceuticals - Orexigen Therapeutics, Inc. - Owen Mumford - PhaseBio Pharmaceuticals - Pfizer - Prometheon Pharma - Roche Diagnostics - Sanofi - Valeritas - ViaCyte, Inc. (formerly Novocell) - Vivus, Inc. - vTv Therapeutics (formerly TransTech Pharma) - Ypsomed Holding For more information visit http://www.researchandmarkets.com/research/8tsk82/diabetes
OREX: 3.43 (-0.08), JNJ: 124.89 (-0.14), ABT: 43.41 (+0.24), VTVT: 5.48 (-0.10), NVO: 55.30 (-0.33), ORMP: 8.02 (-0.04), AMGN: 166.56 (+0.89), GSK: 44.04 (+0.16)
CannScience Innovations Moves to Next Stage of Product Development
CNW Group - Thu Jan 21, 6:00AM CST
Canopy Growth Corporation ("Canopy Growth" or "the Company"
(TSXV: CGC) is pleased to announce that CannScience Innovations Inc. (CSI), operating through a strategic collaboration with the University Health Network, has obtained regulatory approval to conduct research on cannabis. Canopy Growth holds a 33% ownership stake in CSI through its October 2015 acquisition of MedCannAccess. CGC.VN: 3.240 (+0.410)
Deep Vein Thrombosis (DVT) - Global Therapeutics Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/srdbn8/deep_vein) has announced the addition of the "Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis DVT, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis DVT and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Deep Vein Thrombosis DVT Overview - Therapeutics Development - Pipeline Products for Deep Vein Thrombosis DVT - Overview - Pipeline Products for Deep Vein Thrombosis DVT - Comparative Analysis - Deep Vein Thrombosis DVT - Therapeutics under Development by Companies - Deep Vein Thrombosis DVT - Therapeutics under Investigation by Universities/Institutes - Deep Vein Thrombosis DVT - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Deep Vein Thrombosis DVT - Products under Development by Companies - Deep Vein Thrombosis DVT - Products under Investigation by Universities/Institutes - Deep Vein Thrombosis DVT - Companies Involved in Therapeutics Development - 3SBio Inc. - Archemix Corp. - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Laboratorios Farmaceuticos Rovi, S.A. - Merrion Pharmaceuticals Plc For more information visit http://www.researchandmarkets.com/research/srdbn8/deep_vein
BMY: 75.56 (-0.12)
Venous (Vein) Thrombosis Pipeline Review, H2 2015 - Analysis, Technologies & Forecasts
M2 - Thu Jan 07, 11:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/j9d7n9/venous_vein) has announced the addition of the "Venous (Vein) Thrombosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Venous (Vein) Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous (Vein) Thrombosis and special features on late-stage and discontinued projects. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Venous (Vein) Thrombosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Venous (Vein) Thrombosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Venous (Vein) Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Venous (Vein) Thrombosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - 3SBio Inc. - Archemix Corp. - Astellas Pharma Inc. - Bayer AG - Bristol-Myers Squibb Company - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Johnson & Johnson - Laboratorios Farmaceuticos Rovi, S.A. - Merrion Pharmaceuticals Plc - Nihon Pharmaceutical Industry Co., Ltd. For more information visit http://www.researchandmarkets.com/research/j9...enous_vein
JNJ: 124.89 (-0.14), BMY: 75.56 (-0.12)
Global Human Insulin Market 2015-2019 - Increasing R&D for Novel Mechanisms with Eli Lilly, Novo Nordisk & Sanofi Dominating
M2 - Fri Nov 06, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/l7t3hm/global_human) has announced the addition of the "Global Human Insulin Market 2015-2019" report to their offering. The global human insulin market to grow at a CAGR of 10.29% over the period 2014-2019 The report includes the present scenario and the growth prospects of the global human insulin market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of diabetes. The report includes a discussion of the key vendors operating in this market. The key players in the market are extending their support to academic institutions for R&D of innovative products for diabetes care. For instance, Sanofi Diabetes collaborated with academic institutions such as Helmholtz Zentrum and Charite to support R&D in the diabetes care segment. The recent collaboration of Sanofi and Gubra to discover new targets for diabetes is based on the consortium between the University of Copenhagen, Gubra and Gentofte Hospital, which is partly funded by the Danish National Advanced Technology foundation. Such collaborations enable the amalgamation of research expertise of academic institutions with the marketing intelligence of pharma companies, which is expected to support the growth of the market. According to the report, diabetes is managed by the administration of insulin on a lifelong basis. However, insulin-based therapies are incapable of controlling blood glucose levels completely and are often associated with undesirable effects such as nocturnal hypoglycemia. During the fasting stage, glucose utilization increases and free fatty acid utilization decreases in the muscle cells, leading to hypoglycemia. In addition, fat breakdown decreases and fat storage increases in the liver cells, leading to weight gain. Severe hypoglycemic events and weight gain often result in poor patient compliance. Administered insulin therapies have lesser activity in liver and more activity in the periphery as compared to that of endogenous insulin. Therefore, there is a need to develop insulin therapies with better efficacy and safety profile, which is in turn driving market growth. Further, the report states that the global human insulin market is witnessing patent expiries for major brands. Key vendors - Eli Lilly - Novo Nordisk - Sanofi Other prominent vendors - Biocon - Biodel - Biogenomics - Boehringer Ingelheim - Bristol-Myers Squibb - Diamyd Medical - Diasome Pharmaceuticals - DiaVacs - Pfizer - Generex Biotechnology - Lexicon Pharmaceuticals - Macrogenics - Merck - Oramed Pharmaceuticals - Osiris Therapeutics - Thermalin Diabetes - Tolerion - Wockhardt - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/l7...obal_human
NVO: 55.30 (-0.33), LXRX: 15.84 (+0.09), ORMP: 8.02 (-0.04), MRK: 58.56 (-0.26), OSIR: 5.01 (-0.12), LLY: 81.98 (+0.39), BMY: 75.56 (-0.12), XOMA: 0.55 (unch)
Hema Diagnostic Systems, L.L.C. Announces the Final Validation Process for a New Rapid Anthrax Ab Test
ACCESSWIRE - Thu Oct 15, 1:54PM CDT
Hema Diagnostic Systems (HDS) Announces the Final Validation Process of a New Anthrax Toxin Rapid Test for the Detection and Differentiation Between the Anthrax Protective Antigen (PA) and the Lethal Factor (LF) Using Whole Blood or Serum
Generex Announces Memorandum of Understanding in respect of a Phase II Clinical Trial for the Antigen Express Prostate Cancer Vaccine
CNW Group - Thu Oct 15, 8:30AM CDT
Antigen Express to work with CompanDX Ltd. in the UK
Generex proposes acquisition of equity interest in MediTemp
M2 - Wed Oct 14, 7:53AM CDT
Drug delivery company Generex Biotechnology (Other OTC:GNBT) disclosed on Tuesday that it has signed a non-binding Letter of Intent (LOI) with MediTemp.
Generex Announces Agreement to Acquire Equity Interest in MediTemp Ltd.
PR Newswire - Tue Oct 13, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that it has entered into a non-binding Letter of Intent (LOI) with MediTemp Ltd. (MediTemp) (www.meditemp-varicure.com), a private Israeli company that has developed a proprietary cooling technology designed to improve sperm quality in men rendered infertile due to varicoceles.
Generex Announces Agreement to Acquire Equity Interest in Alfa Rhythm Ltd.
CNW Group - Tue Oct 06, 8:30AM CDT
A unique opportunity for GNBT to expand the scope of its business
Hema Diagnostic Systems in Discussions for Equity Investment by Generex Biotechnology Corp.
ACCESSWIRE - Thu Oct 01, 11:44AM CDT
HEMA DIAGNOSTIC SYSTEMS Announces the Execution of A Non-Binding Letter Of Intent with Generex Biotechnology Corporation. HDS And Generex Will Work Together To Bring Technologies Developed By Both Companies Together By Incorporating The New And Novel Rapid Diagnostic Test Systems For Worldwide Market Expansion
Generex Announces Issuance of Buccal Cannabis White Paper
CNW Group - Thu Oct 01, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced the issuance of a white paper on the use of cannabis for medicinal purposes and the joint venture between Generex and CannScience Innovations Inc. (www.cannsci.com) for the design and development of products for the delivery of cannabinoids and cannabinoid-derived formulations into the human body via the buccal mucosa (the inner lining of the mouth).
Generex to purchase 51% equity interest in Hema Diagnostic Systems
M2 - Thu Oct 01, 4:01AM CDT
Drug delivery company Generex Biotechnology (Other OTC:GNBT) disclosed on Wednesday that it has signed a non-binding Letter of Intent (LOI) with Hema Diagnostic Systems (HDS), a Florida company that designs and manufactures proprietary infectious disease detection technologies.
Generex Announces Agreement to Acquire Equity Interest in Hema Diagnostic Systems
CNW Group - Wed Sep 30, 8:30AM CDT
Generex seeks to augment the Antigen Express work In infectious diseases with the HDS detection technologies
European Insulin Market 2015-2019 - Increase in Prevalence of Diabetes with Elli Lilly, Novo Nordisk & Sanofi Dominating the Market
M2 - Mon Sep 21, 10:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tnzhlt/insulin_market_in) has announced the addition of the "Insulin Market in Europe 2015-2019" report to their offering. The insulin market in Europe to grow at a CAGR of 6.50% over the period 2014-2019. The report, Insulin Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the insulin market in Europe and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Growing public awareness of diabetes and the available treatments will likely increase the number of people opting for these treatments. Healthcare companies are organizing awareness camps and discussions to educate people about the condition. These are conducted either alone or in combination with other national institutes. According to the report, changing lifestyle, consumption of high-fat-containing foods, and reduced physical activity increase the prevalence of obesity among the population. Obesity affects the body's normal metabolism, triggering the adipose tissues to release increased amounts of fatty acids, hormones, pro-inflammatory cytokines, and other factors, which are involved in insulin resistance. Further, the report states that the development and regulatory approval of biologic insulin and insulin analog products take longer than small molecules. Minor alterations in the physical structure and chemical pattern can significantly alter the safety and efficacy of these moieties. Unnoticeable variations in the design and execution of a manufacturing process can alter the pharmacokinetic and pharmacodynamics profiles of a drug. Key vendors - Elli Lilly - Novo Nordisk - Sanofi Other prominent vendors - Biodel - Boehringer Ingelheim - Bristol-Myers Squibb - Diamyd Medical - DiaVacs - Generex Biotechnology - Lexicon Pharmaceuticals - Macrogenics - Merck - Osiris Therapeutics - Pfizer - Tolerion - XOMA Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Insulin: An Overview - Market Landscape - Market Segmentation by Type - Buying Criteria - Market Growth Drivers - Drivers and Their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and Their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/tn..._market_in
NVO: 55.30 (-0.33), LXRX: 15.84 (+0.09), MRK: 58.56 (-0.26), OSIR: 5.01 (-0.12), BMY: 75.56 (-0.12)
Thrombosis - Pipeline Review, H1 2015
M2 - Thu Sep 10, 4:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m4rbgj/thrombosis) has announced the addition of the "Thrombosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects. the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Archemix - Arena Pharmaceuticals - Armetheon. - Arrowhead Research - Astellas Pharma - AstraZeneca - Bayer - Bristol-Myers Squibb Company - Cardax Pharmaceuticals - Cereno Scientific - China Biologic Products - CSL - Daewoong Pharmaceutical - Daiichi Sankyo - Eisai - F. Hoffmann-La Roche - Gamma Therapeutics - Generex Biotechnology - GlycoMimetics - Green Cross - IMMD - Isis Pharmaceuticals - Johnson & Johnson - Laboratorios Farmaceuticos Rovi - LG Life Sciences - Lipicard Technologies - Merrion Pharmaceuticals - Nostrum Pharmaceuticals - Pfizer - PLx Pharma - Portola Pharmaceuticals - Prothix BV - Sagene Pharmaceuticals - Sanofi - SciFluor Life Sciences - Tobira Therapeutics. - Zedira For more information visit http://www.researchandmarkets.com/research/m4rbgj/thrombosis
CBPO: 113.14 (+2.50), JNJ: 124.89 (-0.14), PTLA: 24.74 (+0.54), ISIS: 57.56 (-0.28), BMY: 75.56 (-0.12), TBRA: 4.50 (-6.75), ARNA: 1.66 (-0.02)
